# A Study to Evaluate the Efficacy and Safety of Once-Weekly MET097 in Adults With Obesity or Overweight and T2DM

> **NCT06897202** · PHASE2 · COMPLETED · sponsor: **Metsera, a wholly owned subsidiary of Pfizer** · enrollment: 133 (actual)

## Conditions studied

- Obesity in Diabetes
- Type 2 Diabetes Mellitus (T2DM)

## Interventions

- **DRUG:** MET097 Injection
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06897202
- **Lead sponsor:** Metsera, a wholly owned subsidiary of Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2025-03-14
- **Primary completion:** 2026-01-02
- **Final completion:** 2026-03-18
- **Target enrollment:** 133 (ACTUAL)
- **Last updated:** 2026-04-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06897202

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06897202, "A Study to Evaluate the Efficacy and Safety of Once-Weekly MET097 in Adults With Obesity or Overweight and T2DM". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06897202. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*